Clinical trial · Observational
Development of Multi-specific Antibodies Based on Immune Microenvironment of Breast Cancer
NCT05767931CI-TRIAL-00064663unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective, single-center, non-randomized, non-controlled study
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Invasive Breast Cancer | Invasive Breast Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- antitumor rate of multi-specific antibody in patient-derived organoids and PDX model
- timeFrame
- 24 months
- description
- Patient-derived organoids and PDX model
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Women between 18 and 70 years old； 2. Primary lesion \>2cm on imaging examination, or suspected axillary lymph node metastasis on imaging examination； 3. Previous not received preoperative radiotherapy, chemotherapy, endocrine therapy, immunotherapy, or other anticancer treatments； 4. Subjects signed informed consent； Exclusion Criteria: 1. A history of prior or concomitant malignancies; 2. Advanced stage breast cancer (stage IV)； 3. Suspected or confirmed lesion was surgically removed； 4. Patients were accompanied by severe organic diseases such as heart and cerebral disease, and liver and kidney disease.；
References
Publications (0)
Data not yet available
No reference posted for this study.